Literature DB >> 26156546

New Potential Pharmaceutical Applications of Hypericum Species.

Mariangela Marrelli, Giancarlo Statti, Filomena Conforti1, Francesco Menichini.   

Abstract

The genus Hypericum includes more than 450 species distributed in Europe, North America, North Africa and West Asia. These plants are widely used in folk medicine for the treatment of inflammation, bacterial and viral infections, burns and gastric disorders. The use for alleviating inflammation and promoting wound healing is well known for H. Perforatum L. (St. John's wort) and other species. Because of its pharmacological activity, H. perforatum L. is one of the most important species of this genus. This plant has been largely utilized for its efficacy in the treatment of mild to moderate depression. However, some other species have been utilized in traditional medicine and have been studied for their phytochemical composition and for their biological activities to date. Hypericum species contain biologically active secondary metabolites belonging to at least ten different classes, with prevalence of naphthodianthrones (hypericin and pseudohypericin), phloroglucinols (hyperforin), flavonoids (rutin, hyperoside, isoquercitrin, quercitrin, quercetin, amentoflavone) and phenylpropanoids (chlorogenic acid). However, great variations in contents have been reported for wild populations worldwide. The purpose of this review is to provide an overview of most recent studies about potential pharmaceutical applications of plants belonging to Hypericum genus. The most interesting isolated active principles and both in vitro and in vivo effects of Hypericum extracts are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26156546     DOI: 10.2174/1389557515666150709105844

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  7 in total

1.  Hypericum erectum alcoholic extract inhibits Toxoplasma growth and Entamoeba encystation: an exploratory study on the anti-protozoan potential.

Authors:  Noriko Shinjyo; Hideyuki Nakayama; Kanji Ishimaru; Kenji Hikosaka; Fumika Mi-Ichi; Kazumi Norose; Hiroki Yoshida
Journal:  J Nat Med       Date:  2019-11-14       Impact factor: 2.343

2.  Hyperforin/HP-β-Cyclodextrin Enhances Mechanosensitive Ca2+ Signaling in HaCaT Keratinocytes and in Atopic Skin Ex Vivo Which Accelerates Wound Healing.

Authors:  Hiroya Takada; Jun Yonekawa; Masami Matsumoto; Kishio Furuya; Masahiro Sokabe
Journal:  Biomed Res Int       Date:  2017-01-22       Impact factor: 3.411

3.  Chemical Composition and Immunomodulatory Activity of Hypericum perforatum Essential Oils.

Authors:  Igor A Schepetkin; Gulmira Özek; Temel Özek; Liliya N Kirpotina; Andrei I Khlebnikov; Mark T Quinn
Journal:  Biomolecules       Date:  2020-06-17

Review 4.  Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis.

Authors:  Tse-Hung Huang; Chwan-Fwu Lin; Ahmed Alalaiwe; Shih-Chun Yang; Jia-You Fang
Journal:  Int J Mol Sci       Date:  2019-05-24       Impact factor: 6.208

Review 5.  Hypericum Genus as a Natural Source for Biologically Active Compounds.

Authors:  Gonçalo Infante Caldeira; Luís Pleno Gouveia; Rita Serrano; Olga Duarte Silva
Journal:  Plants (Basel)       Date:  2022-09-26

6.  Chitosan oligosaccharides affect xanthone and VOC biosynthesis in Hypericum perforatum root cultures and enhance the antifungal activity of root extracts.

Authors:  Camilla Badiali; Giulia De Angelis; Giovanna Simonetti; Elisa Brasili; Eric de Castro Tobaruela; Eduardo Purgatto; Heng Yin; Alessio Valletta; Gabriella Pasqua
Journal:  Plant Cell Rep       Date:  2018-06-28       Impact factor: 4.570

7.  Antimicrobial Photoinactivation Using Visible Light Plus Water-Filtered Infrared-A (VIS + wIRA) and Hypericum Perforatum Modifies In Situ Oral Biofilms.

Authors:  Andreas Vollmer; Ali Al-Ahmad; Aikaterini Argyropoulou; Thomas Thurnheer; Elmar Hellwig; Thomas Attin; Kirstin Vach; Annette Wittmer; Kerry Ferguson; Alexios Leandros Skaltsounis; Lamprini Karygianni
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.